The First Reliable Estimates of Metastasis Rates in Breast Cancer

For the first time, “reliable” data have been reported on how often women with breast cancer develop metastasis. The data came from an analysis of more than 400 studies involving tens of thousands of women worldwide. Among women who were not metastatic at diagnosis but subsequently developed metastasis, the risk of metastasis was found to range from 6% to 22%, with younger women at greater risk.
Among women diagnosed with breast cancer at age 50 or older, the risk of developing metastasis ranged from 3.7% to 28.6%, while the risk was higher for those diagnosed before age 35 – between 12.7% and 38%. Researchers think this may be because younger women’s tumor biology is more active/aggressive, or because breast screening is less often considered at an early age, leading younger women to be diagnosed at more advanced stages.
- Related topic: Developing breast cancer at a young age
Metastasis risk also varies by tumor type;
- For Luminal B cancers, the risk is between 4.2% and 35.5%
- For Luminal A tumors, the risk is between 2.3% and 11.8%

Eileen Morgan of the International Agency for Research on Cancer said, “Quantifying cancer recurrence and disease progression is important for evaluating treatment effectiveness and prognosis (disease course) and using our resources appropriately and at the right time”.
- Related topic: How often does each cancer RECUR (RETURN)?
Morgan and colleagues presented the results of their analysis of data from many studies at the Sixth International Consensus Conference on Advanced Breast Cancer. They also pointed out that this information had not been available until now because “cancer registries do not routinely collect these data”. After 48 years, the US National Cancer Institute has launched a project to track this information.
What Will Knowing Metastasis Rates Offer Us?
Let us emphasize again that this information provides the first reliable estimate of how many women with breast cancer go on to develop metastasis.
This information is, of course, important to patients who want to understand their prognosis (disease course). But it is also vital at the public health level to help us understand the global scale of the disease in our efforts to treat and prevent advanced breast cancer. It will help identify high-risk groups in different populations/groups and show how the disease course changes with modern treatments. It will also help us understand which resources are needed and where they are, so that we can collect and analyze quality data in real time, a key point for allocating resources and planning future studies.
This study will also provide important motivation for testing highly effective newer-generation cancer drugs currently used in advanced breast cancer (such as CDK 4/6 inhibitors), in early-stage disease at high risk of metastasis.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.